Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Pharmacol Toxicol Methods ; 68(3): 357-66, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23567074

RESUMEN

INTRODUCTION: Preclinical assessment of the heart rate corrected QT interval (QTc) is an important component of the cardiovascular safety evaluation in drug discovery. Here we aimed to quantify the translational relationship between QTc prolongation and shortening in the conscious telemetered dog and humans by a retrospective pharmacokinetic-pharmacodynamic (PKPD) analysis. METHODS: QTc effects of 2 proprietary compounds and 2 reference drugs (moxifloxacin and dofetilide) were quantified in conscious dogs and healthy volunteers via a linear and Emax pharmacokinetic-pharmacodynamic models. The translational relationship was quantified by correlating the QTc response from dog and human at matching free drug concentrations. RESULTS: A consistent translational relationship was found at low delta-QTc intervals indicating that a QTc change of 2.5-8 ms in dog would correspond to a 10 ms change in human. DISCUSSION: The translational relationship developed here can be used to predict the QTc liability in human using preclinical dog data. It could therefore help protect the health of human volunteers, for example by appropriate clinical study design and dose selection, as well as improve future decision-making and help reduce compound attrition due to changes in QT interval.


Asunto(s)
Compuestos Aza/farmacocinética , Síndrome de QT Prolongado/inducido químicamente , Modelos Biológicos , Fenetilaminas/farmacocinética , Quinolinas/farmacocinética , Sulfonamidas/farmacocinética , Adulto , Animales , Compuestos Aza/toxicidad , Compuestos de Azabiciclo/farmacocinética , Compuestos de Azabiciclo/toxicidad , Bencimidazoles/farmacocinética , Bencimidazoles/toxicidad , Carbamatos/farmacocinética , Carbamatos/toxicidad , Ensayos Clínicos Fase I como Asunto , Perros , Método Doble Ciego , Evaluación Preclínica de Medicamentos/métodos , Electrocardiografía , Femenino , Fluoroquinolonas , Humanos , Masculino , Persona de Mediana Edad , Moxifloxacino , Fenetilaminas/toxicidad , Quinolinas/toxicidad , Ensayos Clínicos Controlados Aleatorios como Asunto , Estudios Retrospectivos , Especificidad de la Especie , Sulfonamidas/toxicidad , Telemetría , Investigación Biomédica Traslacional , Adulto Joven
2.
Eur J Clin Pharmacol ; 69(6): 1247-60, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23288352

RESUMEN

PURPOSE: To date, γ-secretase inhibition is the most frequently studied mechanism of reducing Aß in clinical trials with as yet no therapeutic success for AD patients, as measured by the slowing down of cognitive decline or an improvement in cognitive function. The aims of this investigation were to evaluate whether the amyloid hypothesis has been tested clinically, and to explore whether preclinical data are predictive of clinical Aß effects. METHODS: A model-based-meta analysis on Aß levels and drug exposure over time was performed on published and in-house (pre-)clinical data with γ-secretase inhibitors (GSIs; semagacestat, avagacestat, begacestat, PF-3074014, and MK0752). RESULTS: The clinical data available did not show any significant or robust reduction of CNS Aß over time at dose levels intended for AD patients. In contrast, these doses resulted in an average increase in plasma Aß levels over a 24-h interval. A general agreement between preclinical and clinical data was found and allowed for interspecies extrapolations. CONCLUSIONS: More substantially, CNS Aß-lowering drugs are needed to test whether inhibition of Aß production is efficacious in mild AD. Predictions based on preclinical data could assist in the selection of drug candidates and trial design.


Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Secretasas de la Proteína Precursora del Amiloide/antagonistas & inhibidores , Péptidos beta-Amiloides/metabolismo , Encéfalo/efectos de los fármacos , Inhibidores Enzimáticos/uso terapéutico , Modelos Biológicos , Enfermedad de Alzheimer/enzimología , Enfermedad de Alzheimer/psicología , Secretasas de la Proteína Precursora del Amiloide/metabolismo , Péptidos beta-Amiloides/sangre , Animales , Encéfalo/enzimología , Cognición/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Regulación hacia Abajo , Evaluación Preclínica de Medicamentos , Inhibidores Enzimáticos/farmacocinética , Humanos , Especificidad de la Especie , Resultado del Tratamiento
3.
Toxicol Sci ; 126(1): 275-84, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22157355

RESUMEN

The therapeutic value of many drugs can be limited by gastrointestinal (GI) adverse effects such as nausea and vomiting. Nausea is a subjective human sensation, hence little is known about preclinical biomarkers that may accurately and effectively predict its presence in man. The aim of this analysis was to use informatics and data-mining tools to identify plausible preclinical GI effects that may be associated with nausea and that could be of potential use in its prediction. A total of 86 marketed drugs were used in this analysis, and the main outcome was a confirmation that nausogenic and non-nausogenic drugs can be clearly separated based on their preclinical GI observations. Specifically, combinations of common preclinical GI effects (vomiting, diarrhea, and salivary hypersecretion) proved to be strong predictors. The model was subsequently validated with a subset of 20 blinded proprietary small molecules and successfully predicted clinical outcome in 90% of cases. This investigation demonstrated the feasibility of data-mining approaches to facilitate discovery of novel, plausible associations that can be used to understand drug-induced adverse effects.


Asunto(s)
Evaluación Preclínica de Medicamentos/métodos , Drogas en Investigación/efectos adversos , Tracto Gastrointestinal/efectos de los fármacos , Modelos Biológicos , Náusea/inducido químicamente , Animales , Inteligencia Artificial , Análisis por Conglomerados , Gráficos por Computador , Minería de Datos , Diarrea/inducido químicamente , Humanos , Informática Médica/métodos , Medicamentos bajo Prescripción/efectos adversos , Medición de Riesgo/métodos , Sialorrea/inducido químicamente , Vómitos/inducido químicamente
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA